This article explores the 15 stocks receiving the most insider investment in March. Previously, we covered the 10 stocks with the most insider purchases in the last quarter.
“The economy is strong overall and has made significant progress toward our goals over the past two years,” Federal Reserve Chair Jerome Powell said during a press conference Wednesday following the decision announcement. “Labor market conditions are solid, and inflation has moved closer to our 2% longer-run goal, though it remains somewhat elevated.”
The Fed announced on Wednesday that it would maintain the federal funds rate at its current range of 4.25% to 4.5%. It is also keeping its outlook at two rate cuts for the remainder of this year, writes CNBC.
However, the Fed also announced that “uncertainty around the economic outlook has increased.”
Following the announcement, the broader market index rose 1.08%, blue-chip companies gained 0.92% and the NASDAQ Composite jumped 1.41%.
Despite political and economic uncertainty, some analysts remain bullish on AI’s growth. Insider trading draws attention in such times, as executives have unique company insights. For example, when a CEO or CFO buys stock, it may suggest confidence in the company’s future.
However, insider selling doesn’t always signal a lack of faith—it may be due to personal financial needs or asset diversification. Executives often use pre-set plans, like 10b5-1, to ensure transparency and avoid any perception of misconduct.
While insider trading can offer hints, it should be viewed alongside other factors like financial health, market trends, and industry shifts.
An executive in a trading room surrounded by monitors flashing with financial trends.
Our Methodology
Using Insider Monkey’s insider trading screener, we identified stocks with the highest insider purchase values in March.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the total value of insider purchases this month and the company’s current market capitalization. Let’s take a look at the 15 stocks receiving the most insider investment in March.
15. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Total Value of Insider Purchases In March: $9.58 million
Market Capitalization: $1.15 billion
Aurinia Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for autoimmune diseases, where the immune system attacks the body’s own tissues. The company offers LUPKYNIS for lupus nephritis and is developing AUR200 to address other autoimmune conditions. It is also one of the 10 best small-cap growth stocks to buy now.
For the full year 2024, Aurinia reported total revenue of $235.1 million, up 34% from $175.5 million in 2023. Net product sales were $216.2 million, up 36% from $158.5 million in 2023, and net income amounted to $5.8 million, compared to a net loss of $78.0 million in 2023.
In March, one insider bought a total of $9.58 million worth of Aurinia shares at an average price of $8.00 per share. Currently, the stock trades at $8.43 per share, having lost 6.13% year-to-date. However, over the past 12 months, Aurinia returned 64.01% to its investors.
TipRanks reports that four analysts rate Aurinia Pharmaceuticals as a “Strong Buy,” with a 12-month average price target of $9.75, up 15.73% from the latest price.
14. Owens & Minor, Inc. (NYSE:OMI)
Total Value of Insider Purchases In March: $11.06 million
Market Capitalization: $779.43 million
Owens & Minor, together with its subsidiaries, operates as a global healthcare solutions company through two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers medical and surgical supplies—both branded and proprietary—along with services like supplier management, analytics, inventory management, and clinical supply management, while the Patient Direct segment provides in-home care products and services for diabetes treatment, home respiratory therapy, obstructive sleep apnea, and other medical needs. It is one of the 10 best rebound stocks to invest in now.
For the full year 2024, Owens & Minor reported revenues of $10.70 billion, compared to $10.33 billion in 2023. Net loss was $363 million, compared to $41 million in the previous year. For 2025, the company projects revenue in a range of $10.85 billion to $11.15 billion and adjusted EBITDA in a range of $560 million to $590 million.
In March, one insider purchased a total of $11.06 million worth of Owens & Minor shares at an average price of $9.47 per share. The stock trades at $9.77, having declined 25.25% since the beginning of the year, and 62.25% over the past 12 months.
According to StockAnalysis, seven analysts rated Owens & Minor as “Hold” with a price target of $16.07, representing a 64.65% increase from the latest price.
13. Permian Resources Corporation (NYSE:PR)
Total Value of Insider Purchases In March: $12.65 million
Market Capitalization: $11.32 billion
Permian Resources is an independent oil and natural gas company that develops crude oil and liquids-rich natural gas reserves in the United States. Its primary focus is on acreage in the Delaware Basin across Reeves County, Texas, and Lea County, New Mexico. It is one of the 11 stocks that will go to the moon according to Reddit.
For the full year 2024, Permian Resources reported oil and gas sales of $5 billion, compared to oil and gas sales of $3.12 billion in 2023. Operating expenses were $685.17 million, up from $373.77 million in the previous year. Net income amounted to $1.25 billion, up from $879.7 million in 2023.
In March, one insider bought a total of $12.65 million worth of Permian Resources shares at an average price of $12.50 per share. Currently, the stock trades at $14.06, having declined 2.23% year-to-date, and 17.54% over the past 12 months.
Based on 18 Wall Street analysts, the average price target on Permian Resources stock is $19.19, representing a 36.39% increase from the latest price. According to TipRanks, the stock also holds a “Strong Buy” rating.
12. Prospect Capital Corporation (NASDAQ:PSEC)
Total Value of Insider Purchases In March: $12.73 million
Market Capitalization: $1.9 billion
Prospect Capital is a business development company that invests in middle-market and later-stage businesses through secured loans, mezzanine debt, private equity, and real estate financing. Its diversified portfolio includes industries such as manufacturing, energy, healthcare, and media. On January 31, 2025, Prospect Capital announced a $65 million investment in Taos Footwear via senior secured loans and preferred equity. It is one of the 12 cash-rich penny stocks to buy according to hedge funds.
For the fiscal quarter ended December 31, 2024, Prospect Capital reported a net loss of $30.99 million, compared to a net loss of $51.44 million in the same period of 2023. The company has long-term debts that will be paid off over the next 27 years. As of December 2024, Prospect Capital had $1.9 billion in available cash and credit, and $4.8 billion of its assets were free from any debt or obligations.
In March, two insiders, including the company’s CEO, acquired a total of $12.73 million worth of Prospect Capital shares at an average price of $4.27 per share. Year-to-date the stock is down 0.93%, trading at $4.27 per share. Over the past 12 months, Prospect Capital shares declined 21.79%.
According to MarketBeat, one analyst gave Prospect Capital a “Sell” rating with a price target of $4.50, indicating a potential upside of 5.26% from the latest price.
11. Zymeworks Inc. (NASDAQ:ZYME)
Total Value of Insider Purchases In March: $15.99 million
Market Capitalization: $889.89 million
Zymeworks is a clinical-stage biopharmaceutical company that develops biotherapeutics for cancer treatment, with lead candidates including zanidatamab, a human epidermal growth factor receptor 2 (HER2) in Phases 1-3 clinical trials, and zanidatamab zovodotin, a Phase 2 HER2-targeted antibody-drug conjugate. The Middletown, Delaware-based company also explores preclinical oncology programs and collaborates with partners like BeiGene, Celgene, GlaxoSmithKline, and Merck Sharp & Dohme, among others.
For the full year 2024, Zymeworks reported revenue of $76.3 million, compared to $76.0 million in 2023. Revenue for 2024 included $25.0 million in milestone revenue from Jazz related to FDA approval of Ziihera (zanidatamab-hrii) for HER2+ BTC treatment. Research and development expense was $134.6 million in 2024 compared to $143.6 million in 2023. Net loss was $122.7 million in 2024 compared to a $118.7 million loss in 2023. As of December 31, the company had $324.2 million of cash resources consisting of cash, cash equivalents and marketable securities.
In March, one insider purchased a total of $15.99 million Zymeworks shares at an average price of $12.29 per share. The stock trades at $12.96 having declined 11.48% year-to-date. However, over the past 12 months, its shares returned 20.56% to investors.
According to six analysts, Zymeworks stock has an average rating of “Buy,” with a price target of $19.50, indicating a 50.93% upside from the latest price, writes StockAnalysis.
10. BlackRock ESG Capital Allocation Term Trust (NYSE:ECAT)
Total Value of Insider Purchases In March: $17.23 million
Market Capitalization: $1.61 billion
BlackRock ESG, a newly established, non-diversified, closed-end management investment company with no operating history, ranks 10th among the 15 stocks insiders spent the most money on this month. Headquartered in Wilmington, DE, the company aims to deliver total return and income through a mix of current income, gains, and long-term capital appreciation.
In March, one insider bought a total of $17.23 million worth of BlackRock ESG shares at an average price of $16.38 per share. Currently, the stock trades at $16.27, having lost 0.79% year-to-date and 3.61% over the past 12 months.
The analyst coverage on BlackRock ESG stock is currently limited.
9. CVR Energy, Inc. (NYSE:CVI)
Total Value of Insider Purchases In March: $17.27 million
Market Capitalization: $2.2 billion
CVR Energy is a diversified holding company primarily focused on renewable fuels, petroleum refining, marketing, and nitrogen fertilizer manufacturing through its subsidiary, CVR Partners, LP. CVR Energy is one of billionaire hedge fund manager Carl Icahn’s top 10 stock picks.
In 2024, the company’s revenue amounted to $7.61 billion, reflecting a 17.7% decrease compared to the previous year’s $9.25 billion. Net income attributable to CVR Energy shareholders was $7 million, or 6 cents per diluted share, compared to net income of $769 million, or $7.65 per share in 2023. The adjusted loss was 51 cents per diluted share, compared to adjusted earnings of $5.64 per diluted share in the previous year.
In March, one insider acquired a total of $17.27 million worth of CVR Energy shares at an average price of $18.07 per share. The stock rose 14.62% since the beginning of the year and now trades at $21.48. Over the past 12 months, its shares lost 41.60%.
Twelve analysts rate CVR Energy, Inc. as a “Hold,” with a price target of $31.73, suggesting a potential upside of 44.77% from the latest price, writes MarketBeat.
8. Victoria’s Secret & Co. (NYSE:VSCO)
Total Value of Insider Purchases In March: $19.51 million
Market Capitalization: $1.71 billion
Victoria’s Secret & Co. is a retailer specializing in women’s intimates, apparel, and beauty products, operating under the Victoria’s Secret, Victoria’s Secret PINK, and Adore Me brands. Its product range includes sleepwear, loungewear, swimwear, athleisure, lingerie, prestige fragrances, and body care items. The company is based in Reynoldsburg, Ohio, and is also considered one of 12 best apparel stocks to invest in.
For fiscal 2024, Victoria’s Secret & Co. disclosed net sales of $6.23 billion, up by 1% from $6.18 billion in fiscal 2023. Net income amounted to $165 million, or $2.05 per diluted share, compared to net income of $109 million, or $1.39 per diluted share for fiscal year 2023.
The company is forecasting net sales for the first quarter of 2025 to be in the range of $1.30 billion to $1.33 billion compared to last year’s first quarter net sales of $1.36 billion. At this forecasted level of net sales, adjusted operating income for the first quarter of 2025 is expected to be in the range of $10 million to $30 million.
In March, one insider purchased a total of $19.51 million worth of Victoria’s Secret & Co. shares at an average price of $16.91 per share. The stock trades at $21.89, having lost 47.15% since the beginning of the year. Over the past 12 months, Victoria’s Secret & Co. shares returned 11.91% to its investors.
According to StockAnalysis, 12 analysts rate Victoria’s Secret & Co. stock as a “Hold,” with a 12-month price target of $33.00, suggesting a potential upside of 51.41% from the latest price.
7. TriMas Corporation (NASDAQ:TRS)
Total Value of Insider Purchases In March: $21.5 million
Market Capitalization: $1.03 billion
TriMas Corporation designs, manufactures and sells products for consumer, aerospace, and industrial markets worldwide through its Packaging, Aerospace, and Specialty Products segments. Headquartered in Bloomfield Hills, Michigan, the company offers dispensing products, aerospace fasteners and components, and steel cylinders for gas storage, selling through direct sales, agents, and distributors.
For the full year 2024, TriMas reported net sales of $925 million, an increase of 3.5% compared to 2023, as robust sales growth in its Packaging and Aerospace segments was partially offset by a sales decline of 37.2% in the Specialty Products segment, primarily due to market inventory adjustments, compared to the prior year. The company disclosed an operating profit of $47.2 million in 2024, as compared to $65.4 million in 2023. Net income amounted to $24.3 million or $0.59 per diluted share, compared to $40.4 million, or $0.97 per diluted share in 2023.
In March, three insiders bought a total of $21.5 million worth of TriMas shares at an average price of $22.83 per share. Currently, the stock trades at $25.18 per share, having dropped 2.40% year-to-date, and 2.21% over the past 12 months.
One analyst has given a “Buy” rating to TriMas stock with a price target of $40.00, suggesting a 60.16% upside, according to MarketBeat.
6. Immunocore Holdings plc (NASDAQ:IMCR)
Total Value of Insider Purchases In March: $23.99 million
Market Capitalization: $1.44 billion
Immunocore is a commercial-stage biotechnology company that develops immunotherapies for cancer, infectious, and autoimmune diseases. Its key products include KIMMTRAK for metastatic uveal melanoma and various oncology and infectious disease treatments in clinical trials, such as tebentafusp, brenetafusp, and IMC-M113V for HIV. The biotech is based in Abingdon, UK.
For the fourth quarter and year ended December 31, 2024, the company reported net sales of $84.1 million and $310.2 million, respectively, arising from the sale of KIMMTRAK, of which $63.8 million and $226.7 million, respectively was in the United States. Net sales compare to $249.43 million in 2023. Net loss for the quarter and year ended December 31, 2024, was $23.8 million and $51.1 million, respectively, as compared to $19.7 million and $55.3 million, respectively, for the same periods in 2023.
In March, one insider acquired $23.99 million worth of Immunocore shares at an average price of $29.65 per share. Year-to-date, the stock is up 4.81%, trading at $30.92 per share. Over the past 12 months, Immunocore shares declined 50.84%.
Twelve analysts rate Immunocore stock as a “Buy,” with a 12-month price target of $63.00, indicating a potential upside of 119.4% from the last price, according to StockAnalysis.
5. Venture Global, Inc. (NYSE:VG)
Total Value of Insider Purchases in March: $24.44 million
Market Capitalization: $27.1 billion
Venture Global ranks fifth among the 15 stocks with the highest insider purchases this March. The Arlington, Virginia-based company develops and constructs natural gas liquefaction and export projects near the Gulf of Mexico in Louisiana.
For the full year 2024, the company disclosed revenue of $4.97 billion, compared to $7.9 billion in 2023. Net income amounted to $1.48 billion, which compares to $2.68 billion in the prior year. Consolidated adjusted EBITDA was $2.1 billion, compared to $5.16 billion in 2023. For the full year 2025, Venture Global projects adjusted EBITDA in the range of $6.8 billion to $7.4 billion.
In March, three insiders purchased $24.44 million worth of Venture Global shares at an average price of $10.21 per share. Since its initial public offering this January, Venture Global shares declined 53.33%.
Based on estimates from 10 analysts, Venture Global has a “Moderate Buy” rating with a price target of $17.78, suggesting a 58.75% upside, according to TipRanks.
4. Janux Therapeutics, Inc. (NASDAQ:JANX)
Total Value of Insider Purchases in March: $25.34 million
Market Capitalization: $1.83 billion
Janux Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapies using its TRACTr and TRACIr platform technologies. Its clinical candidates include JANX007 for metastatic castration-resistant prostate cancer and JANX008 for various solid cancers, both in Phase 1 trials. The San Diego, California-based company collaborates with Merck Sharp & Dohme Corp. to develop its TRACTr therapies.
For the full year 2024, the company disclosed a net loss of $69.0 million, compared to $58.3 million in 2023. Research and development expenses were $68.4 million, which compares to $54.9 million for 2023. As of December 31, 2024, Janux reported cash and cash equivalents and short-term investments of $1.03 billion compared to $344.0 million on December 31, 2023.
In March, one insider bought $25.34 million worth of Janux Therapeutics shares at an average price of $30.92 per share. The stock trades at $30.91 per share, down 42.27% year-to-date and 21.01% over the past 12 months.
According to StockAnalysis, 10 analysts rate Janux Therapeutics stock as a “Strong Buy,” with a 12-month price target of $84.00, up 171.76% from its current price.
Janux Therapeutics is also among the 10 worst high-risk high-reward growth stocks to buy.
3. Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
Total Value of Insider Purchases in March: $33.7 million
Market Capitalization: $1.05 billion
Mineralys Therapeutics is a clinical-stage biopharmaceutical company that develops medicines targeting diseases caused by dysregulated aldosterone. Its main product, lorundrostat, is in Phase 2 trials for hypertension and chronic kidney disease, with a pivotal program for resistant hypertension. The biotech is based in Radnor, Pennsylvania and is also one of the 10 Pump and Dump Stocks Favored by Hedge Funds.
Mineralys Therapeutics recently reported positive results from two key hypertension trials for lorundrostat. The Launch-HTN trial showed a significant systolic blood pressure reduction of 9.1 mmHg at week 6, sustained through week 12, while the Advance-HTN trial, conducted with the Cleveland Clinic, demonstrated a 7.9 mmHg reduction at week 12. Lorundrostat was well-tolerated in both trials, with minimal impact on potassium levels.
In March, three insiders bought a total of $33.7 million worth of Mineralys Therapeutics shares at a price of $13.50 per share. Since the beginning of the year, the stock rose 36.07% and currently trades at $16.75. Over the past 12 months, Mineralys Therapeutics shares returned 25.09% to its investors.
According to four analysts, Mineralys Therapeutics has an average rating of “Buy” with a 12-month price target of $27.00. The average price target represents an upside of 61.19% from its last price, writes MarketBeat.
2. FirstSun Capital Bancorp (NASDAQ:FSUN)
Total Value of Insider Purchases in March: $38.00 million
Market Capitalization: $1.06 billion
FirstSun Capital operates as a bank holding company for Sunflower Bank providing commercial and consumer banking services in Texas, Kansas, Colorado, New Mexico, and Arizona. The Denver, Colorado-based company offers various deposit and loan products, wealth management, online banking, and trust services for small and medium-sized businesses and consumers.
For the full year 2024, FirstSun disclosed a net income of $75.6 million, or $2.69 per diluted share, compared to $103.5 million, or $4.08 per diluted share in 2023. The return on average total assets was 0.96% in 2024, compared to 1.38% in 2023, and the return on average stockholders’ equity was 7.56% in 2024, compared to 12.50% in 2023.
In March, one insider purchased a total of $38 million worth of FirstSun shares at a price of $37.06 per share. Year-to-date, the stock is down 4.72% trading at $38.16. Over the past 12 months, FirstSun shares gained 6.89%.
Three Wall Street analysts rate FirstSun Capital Bancorp a “Strong Buy,” with an average 12-month price target of $48.00. The average price target suggests 25.79% upside from its last price, according to TipRanks.
1. Tenaya Therapeutics, Inc. (NASDAQ:TNYA)
Total Value of Insider Purchases in March: $49.99 million
Market Capitalization: $113.45 million
First among the 15 stocks insiders have been spending money on in March, is a biotech Tenaya Therapeutics. The South San Francisco, California-based company, discovers, develops, and delivers therapies for heart disease in the United States.
For the full year 2024, Tenaya Therapeutics disclosed a net loss of $111.1 million, or $1.31 per share, compared to $124.08 million in 2023. Research and development expenses amounted to $86.7 million, compared to $98.0 million in the prior year.
As of December 31, 2024, cash, cash equivalents and investments in marketable securities were $61.4 million, compared to $104.6 million as of December 31, 2023. With the additional estimated net proceeds of $48.9 million from the March 2025 public offering, the company expects that its current funds are sufficient to support planned company operations into mid-2026.
In March, two insiders purchased a total of close to $50 million worth of Tenaya Therapeutics shares at an average price of $0.70 per share. Currently, the stock trades at $0.70, having declined 51.20% year-to-date, and 85.76% over the past 12 months.
According to StockAnalysis, six analysts rate Tenaya Therapeutics stock as a “Strong Buy,” with a 12-month price forecast of $8.60—an increase of 1,132.09% from its current price.
Overall, TNYA ranks first among the 15 stocks insiders are spending the most money on in March. While we acknowledge the potential of TNYA, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TNYA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
